EDIT
Editas Medicine, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.23
+4.87%0
Insider buys (3m)
2
Insider sells (3m)
-$14.9K
Net value (3m)
+14.5%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 7, 2026 | Ellinor Patrick Thomas II · director | A-Award | 103,400 | $2.90 |
| Aug 5, 2026 | Parison Amy · officer: SVP, Chief Financial Officer | Sale | 678 | $2.58 |
| Jul 29, 2026 | Burkly Linda · officer: EVP, CHIEF SCIENTIFIC OFFICER | Sale | 4,928 | $2.67 |
| Jun 22, 2026 | Levy Elliott M. · director | A-Award | 51,700 | $2.55 |
| Jun 22, 2026 | Hirsch Andrew · director | A-Award | 51,700 | $2.55 |
| Jun 22, 2026 | Hopfield Jessica · director | A-Award | 51,700 | $2.55 |
| Jun 22, 2026 | Scadden David · director | A-Award | 51,700 | $2.55 |
| Jun 22, 2026 | Connaughton Bernadette · director | A-Award | 51,700 | $2.55 |
| Jun 5, 2026 | Burkly Linda · officer: EVP, CHIEF SCIENTIFIC OFFICER | Sale | 731 | $2.70 |
| Jun 5, 2026 | Parison Amy · officer: SVP, Chief Financial Officer | Sale | 464 | $2.70 |
| Jun 5, 2026 | O'Neill Gilmore Neil · director, officer: CEO | Sale | 15,380 | $2.70 |
| Mar 16, 2026 | Burkly Linda · officer: EVP, CHIEF SCIENTIFIC OFFICER | A-Award | 292,856 | $2.54 |
| Mar 16, 2026 | O'Neill Gilmore Neil · director, officer: CEO | A-Award | 1,015,200 | $2.54 |
| Mar 16, 2026 | Parison Amy · officer: SVP, Chief Financial Officer | A-Award | 292,856 | $2.54 |
| Mar 4, 2026 | O'Neill Gilmore Neil · director, officer: CEO | Sale | 5,394 | $2.02 |
| Mar 4, 2026 | Burkly Linda · officer: EVP, CHIEF SCIENTIFIC OFFICER | Sale | 749 | $2.02 |
| Mar 4, 2026 | Parison Amy · officer: SVP, Chief Financial Officer | Sale | 474 | $2.02 |
| Dec 4, 2025 | Parison Amy · officer: SVP, Chief Financial Officer | Sale | 461 | $2.15 |
| Dec 4, 2025 | Burkly Linda · officer: EVP, CHIEF SCIENTIFIC OFFICER | Sale | 713 | $2.15 |
| Dec 4, 2025 | O'Neill Gilmore Neil · director, officer: CEO | Sale | 5,603 | $2.15 |
| Sep 4, 2025 | O'Neill Gilmore Neil · director, officer: CEO | Sale | 5,592 | $2.60 |
| Sep 4, 2025 | Burkly Linda · officer: EVP, CHIEF SCIENTIFIC OFFICER | Sale | 710 | $2.60 |
| Sep 4, 2025 | Parison Amy · officer: SVP, Chief Financial Officer | Sale | 458 | $2.60 |
| Aug 8, 2025 | Parison Amy · officer: SVP, Chief Financial Officer | Sale | 679 | $2.58 |
| Aug 4, 2025 | Burkly Linda · officer: EVP, CHIEF SCIENTIFIC OFFICER | Sale | 5,121 | $2.49 |
| Jun 10, 2025 | Connaughton Bernadette · director | A-Award | 37,500 | $1.91 |
| Jun 10, 2025 | Hopfield Jessica · director | A-Award | 37,500 | $1.91 |
| Jun 10, 2025 | Hirsch Andrew · director | A-Award | 37,500 | $1.91 |
| Jun 10, 2025 | Levy Elliott M. · director | A-Award | 37,500 | $1.91 |
| Jun 10, 2025 | Scadden David · director | A-Award | 37,500 | $1.91 |
Institutional positioning
13F filings over the trailing two quarters
New 76Increased 136Reduced 95Sold out 24
| Filer | Action | Shares | Filed |
|---|---|---|---|
| TCG Crossover Management, LLC | New Position | 11,111,111 | Aug 14, 2026 |
| BlackRock, Inc. | Increased | 10,589,990 | Aug 7, 2026 |
| BLACKROCK, INC. | Reduced | 9,263,312 | May 13, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | New Position | 8,889,000 | Aug 14, 2026 |
| Commodore Capital LP | New Position | 8,889,000 | Aug 14, 2026 |
| ADAR1 Capital Management, LLC | New Position | 8,889,000 | Aug 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 6,141,336 | Aug 13, 2026 |
| Paradigm Biocapital Advisors LP | New Position | 5,586,625 | Aug 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 4,204,369 | May 15, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | Increased | 3,972,160 | May 14, 2026 |
| Opaleye Management Inc. | Increased | 3,861,930 | Aug 14, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | Increased | 3,598,339 | Aug 13, 2026 |
| Woodline Partners LP | New Position | 3,555,497 | Aug 14, 2026 |
| Vivo Capital, LLC | New Position | 3,555,250 | Aug 14, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | New Position | 3,148,570 | May 8, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 7, 2026